Similar articles

• Cytotoxicity against tumour-associated antigens not H-2 restricted.

  Holden HT, Herberman RB. Holden HT, et al. Nature. 1977 Jul 21;268(5617):250-2. doi: 10.1038/268250a0. Nature. 1977. PMID: 69992 No abstract available.
• The immune response to primary Moloney sarcoma virus tumors in BALB-c mice: cellular and humoral activity of long-term regressors.

  Lamon EW, Anderson B, Wigzell H, Fenyö EM, Klein E. Lamon EW, et al. Int J Cancer. 1974 Jan 15;13(1):91-104. doi: 10.1002/ijc.2910130111. Int J Cancer. 1974. PMID: 4594340 No abstract available.
• In vivo growth and antigenic properties of a rat sarcoma induced by Moloney sarcoma virus.

  Jones JM, Jensen F, Veit B, Feldman JD. Jones JM, et al. J Natl Cancer Inst. 1974 Jun;52(6):1771-7. doi: 10.1093/jnci/52.6.1771. J Natl Cancer Inst. 1974. PMID: 4134500 No abstract available.
• Embryonic antigens in tumor immunity.

  Della Porta G. Della Porta G. Johns Hopkins Med J Suppl. 1974;3:279-87. Johns Hopkins Med J Suppl. 1974. PMID: 4138923 Review. No abstract available.
• Tumor-associated membrane antigens and the antitumor immune reactions.

  Levy JP, Kourilsky FM. Levy JP, et al. Transplant Proc. 1973 Dec;5(4):1435-40. Transplant Proc. 1973. PMID: 4130056 Review. No abstract available.